{
  "documentMetadata": {
    "title": "Lymphadenitis, Nocardia",
    "sourceFile": "lymph_nodes-spleen/lymphadenitis/Lymphadenitis, Nocardia.pdf"
  },
  "content": [
    {
      "type": "header",
      "level": 1,
      "text": "Clinical Setting"
    },
    {
      "type": "list",
      "items": [
        "Regional nodular lymphadenitis with or without skin abscesses.",
        "History of cutaneous injury may be present.",
        "Culture positive for Nocardia sp.",
        "No evidence of dissemination."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Etiologies"
    },
    {
      "type": "paragraph",
      "text": "Over 40 species of Nocardia have been identified in human infections (Clin Microbiol Rev. 2006; 19:259; Clin Microbiol Rev. 2022; 35:e0002721). The more common are listed below."
    },
    {
      "type": "list",
      "items": [
        "Nocardia nova complex",
        "Nocardia farcinica",
        "Nocardia cyriacigeorgica",
        "Nocardia brasiliensis",
        "Nocardia abscessus"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Primary Regimens"
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "components": [
          {
            "drug": "TMP-SMX",
            "dose": "5-10 mg/kg/day (based on TMP component)",
            "route": "IV/po",
            "frequency": "divided in 2-4 doses"
          }
        ],
        "durationDetail": {
          "fixedDuration": "3-6 months if patient is immunocompetent and 6-12 months if immunocompromised"
        }
      }
    },
    {
      "type": "header",
      "level": 1,
      "text": "Alternative Regimens"
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "components": [
          {
            "drug": "Minocycline",
            "dose": "100-200 mg",
            "route": "po",
            "frequency": "bid"
          }
        ]
      }
    },
    {
      "type": "header",
      "level": 1,
      "text": "Comments"
    },
    {
      "type": "list",
      "items": [
        "Therapy should be guided by in vitro susceptibility tests (See Antimicrob Agents Chemother 58:795, 2014 for susceptibility profiles according to species). In vitro resistance to TMP-SMX is uncommon and not clearly predictive of treatment failure with this agent (J Clin Microbiol. 2012;50:670-2).",
        "Other agents with in vitro activity against some strains, although there is little if any clinical efficacy data: Amoxicillin-clavulanate, Ceftriaxone, Clarithromycin (Clin Microbiol Infect 17:690, 2011; Clin Microbiol Infect 12:905, 2006; Medicine 88:250, 2009).",
        "Linezolid 600 mg po bid is reported effective (Ann Pharmacother 41:1694, 2007)."
      ]
    }
  ]
}
